ARTHEx Biotech

Valencia, Spain

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

$40.6M raised

Sep 2025

Series B

Biotechnology

Top Investors

BpifranceEuropean Innovation CouncilColumbus Venture PartnersSound BioventuresHadean Ventures

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about ARTHEx Biotech

How much funding has ARTHEx Biotech raised?

ARTHEx Biotech has raised $40.6M in total funding. The most recent round was Series B. The last funding was announced in September 2025.

Who are ARTHEx Biotech's investors?

ARTHEx Biotech's investors include Bpifrance, European Innovation Council, Columbus Venture Partners, Sound Bioventures, Hadean Ventures.

Where is ARTHEx Biotech headquartered?

ARTHEx Biotech is headquartered in Valencia, Spain.

What does ARTHEx Biotech do?

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

What stage is ARTHEx Biotech at?

ARTHEx Biotech is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 17, 2025.

MLA

"ARTHEx Biotech — Funding & Investors." VCBacked, September 17, 2025, https://www.vcbacked.co/company/arthex-biotech. Accessed June 4, 2026.

APA

VCBacked. (2025). ARTHEx Biotech — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/arthex-biotech

Wikipedia (cite web)

{{cite web |title=ARTHEx Biotech — Funding & Investors |url=https://www.vcbacked.co/company/arthex-biotech |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 17, 2025.

Similar Companies in Biotechnology